Conditions: Psoriatic Arthritis
Keywords: Psoriatic Arthritis PsA Commercial product American College of Rheumatology ACR/PASI
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 110
Healthy volunteers: no

Brief summary:
The overall objective of the study was to describe the long-term effectiveness and safety of etanercept in patients with psoriatic arthritis in a Canadian clinical practice setting.

Detailed description:

Arms:
arm 1: Open-label etanercept administered by subcutaneous injection at a dose of 50 mg/week for 24 months.

Interventions: intervention 1: Etanercept
Intervention descriptions: intervention 1: Administered according to the product monograph by subcutaneous (SC) injection

Protocol document: